Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001)

被引:44
作者
Sader, HS [1 ]
Biedenbach, DJ
Jones, RN
机构
[1] JMI Labs, JONES Grp, N Liberty, MA USA
[2] Univ Fed Sao Paulo, Sao Paulo, Brazil
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
D O I
10.1016/S0732-8893(03)00052-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A total of 48,440 Enterobacteriaceae isolates collected consecutively from patients hospitalized in participant SENTRY Antimicrobial Surveillance Program sites in four international regions (Asia-Pacific, Europe, Latin America, and North America) were tested by reference broth microdilution method against the most commonly used antimicrobial agents. The most active compounds could be divided in 3 groups based on their spectrum of activity. The first group included meropenem and imipenem, with 99.9% susceptibilty (S) rates for the Enterobacteriaceae. The second group includes amikacin (97.3% S) and cefepime (97.2% S); and a third active group had a rank order of susceptibility of: gatifloxacin = levofloxacin (91.7% S) > ceftazidime (91.4% S) > ceftriaxone (91.2% S) > aztreonam (91.1% S) > gentamicin (90.6% S) > piperacillin/tazobactam = ciprofloxacin (90.5% susceptibility). These latter antimicrobial agents presented susceptibility rates of approximately 90% (89.8%-91.7%). Continued resistance surveillance by various programs remain necessary to monitor the in vitro effectiveness of antimicrobial agents currently used in clinical practice. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:361 / 364
页数:4
相关论文
共 15 条
[1]   A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides [J].
Ali, MZ ;
Goetz, MB .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :796-809
[2]  
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[3]   CEFEPIME - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE [J].
BARRADELL, LB ;
BRYSON, HM .
DRUGS, 1994, 47 (03) :471-505
[4]  
Diekema DJ, 1999, CLIN INFECT DIS, V29, P595, DOI 10.1086/598640
[5]   Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients [J].
Harris, AD ;
Smith, D ;
Johnson, JA ;
Bradham, DD ;
Roghmann, MC .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) :340-345
[6]   The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting [J].
Ibrahim, EH ;
Sherman, G ;
Ward, S ;
Fraser, VJ ;
Kollef, MH .
CHEST, 2000, 118 (01) :146-155
[7]   Resistance patterns among nosocomial pathogens - Trends over the past few years [J].
Jones, RN .
CHEST, 2001, 119 (02) :397S-404S
[8]   Antimicrobial activity of broad-spectrum agents tested against Gramnegative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001) [J].
Jones, RN ;
Varnam, DJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (04) :379-382
[9]   Microbiology of newer fluoroquinolones: focus on respiratory pathogens [J].
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (03) :213-220
[10]   Summation:: β-lactam resistance surveillance in the Asia-Western Pacific region [J].
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 35 (04) :333-338